PDCD1 and lung carcinoma: According to our saturation experimental design (Figure 1B), we noted that 0.1 μg/mL Nivolumab saturated 80% of PD-1 expressed on the surface of H1975 lung cancer cells (H1975NivoSat) (Figure 1C).